RecruitingNCT06693531
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Studying NON RARE IN EUROPE: Eosinophilic esophagitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- dupilumab(drug)
- Enrollment
- 350 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arizona Digestive Health/GI Alliance, Sun City, Arizona, United States
- Arkansas Childrens Hospital, Little Rock, Arkansas, United States
- Scripps Clinic, La Jolla, California, United States
- University of California Los Angeles (UCLA), Los Angeles, California, United States
- University of Southern California Keck School of Medicine, Los Angeles, California, United States
- University of California, San Francisco, Oakland, California, United States
- University of California San Francisco (UCSF), San Francisco, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Rocky Mountain Gastroenterology, Littleton, Colorado, United States
- UConn Health - The Carole and Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- Gastroenterology of Greater Orlando, Orange City, Florida, United States
- Orlando Health, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06693531 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Eosinophilic esophagitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07112378A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRegeneron Pharmaceuticals
- RECRUITINGNCT07156357Surface EMG Testing on Swallowing in EoE PatientsMayo Clinic
- RECRUITINGNCT06972147Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic EsophagitisUniversity Hospital, Angers
- RECRUITINGNCT07012928Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II InflammationAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- RECRUITINGPHASE2NCT05485155Zemaira Eosinophilic Esophagitis Pilot StudyChildren's Hospital Medical Center, Cincinnati
- ENROLLING BY INVITATIONNANCT06756581Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein TriggerShaare Zedek Medical Center
- RECRUITINGPHASE2NCT06705387Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoEUniversity of Colorado, Denver
- RECRUITINGPHASE4NCT06665971Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)University of California, San Diego
See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis →